Transforming cancer care through the power of blood.
We believe that a simple blood draw should be enough to detect cancer earlier, guide treatment decisions, and monitor for recurrence — sparing patients from invasive biopsies and enabling oncologists to act with confidence.
Conquer cancer with data, not guesswork.
Guardant Health was founded on a single conviction: that the information locked inside a patient's blood could revolutionize how we detect and treat cancer. Since 2012, we have built the world's leading liquid biopsy platform — one that turns a routine blood draw into a comprehensive genomic portrait of a patient's cancer.
Our tests are used by more than 10,000 oncologists across the United States and in over 50 countries. Every result we deliver is backed by rigorous science, validated in peer-reviewed studies, and designed to give clinicians the clarity they need to make the best possible decisions for their patients.
Science first
Every product we build is grounded in rigorous analytical and clinical validation before it reaches a patient.
Patient-centered
We measure our success by patient outcomes — earlier detection, better therapy matching, longer survival.
Broad access
We work to ensure that liquid biopsy is available to every patient who needs it, regardless of geography or resources.
Clinical partnership
We partner with oncologists, researchers, and health systems to continuously improve our platform and expand its utility.
A decade of breakthroughs.
Guardant Health founded by Helmy Eltoukhy and AmirAli Talasaz
Guardant360 launched — the first comprehensive liquid biopsy for advanced solid tumors
IPO on Nasdaq; first liquid biopsy company to reach public markets
Guardant360 CDx receives FDA approval as companion diagnostic for NSCLC
Guardant Reveal launched for early-stage MRD monitoring
Shield receives FDA approval as first blood-based colorectal cancer screening test
The team behind the science.
Helmy Eltoukhy
Co-Founder & Executive Chairman
Helmy co-founded Guardant Health in 2012 after pioneering next-generation sequencing technology at Stanford. He has led the company from a research concept to a publicly traded precision oncology leader.
AmirAli Talasaz
Co-Founder & CEO
AmirAli co-founded Guardant Health and serves as Chief Executive Officer. He oversees the company's strategic direction, product development, and global commercial operations.
Michael Bell
Chief Financial Officer
Michael brings deep experience in healthcare finance and capital markets, overseeing Guardant's financial strategy, investor relations, and corporate development.
Stefanie Mandel
Chief Commercial Officer
Stefanie leads Guardant's commercial organization, driving adoption of the company's liquid biopsy portfolio across oncology practices, health systems, and payer channels.
Richard Lanman, MD
Chief Medical Officer
Dr. Lanman oversees clinical development, medical affairs, and the scientific strategy underpinning Guardant's product portfolio and evidence generation programs.
Darya Chudova, PhD
Chief Scientific Officer
Darya leads Guardant's research and development organization, directing the scientific innovation that powers the company's next-generation liquid biopsy technologies.
Building the future of cancer detection.
Beyond our commercial portfolio, Guardant is advancing a pipeline of next-generation liquid biopsy applications that will expand the reach of blood-based cancer testing.
Multi-cancer early detection
Expanding Shield's technology platform to detect multiple cancer types from a single blood draw in average-risk screening populations.
Therapy response monitoring
Real-time ctDNA kinetics to assess treatment response and guide adaptive therapy decisions during active treatment.
Hereditary cancer risk
Germline variant detection from blood to identify patients with inherited cancer predisposition syndromes.
Proteomics + ctDNA integration
Multi-analyte platform combining circulating tumor DNA with protein biomarkers for enhanced sensitivity and specificity.
Ready to bring liquid biopsy to your patients?
Talk to a Guardant Health representative or explore our test portfolio to find the right solution for your practice.